3 results about "Leishmania" patented technology

The present invention relates to the use of parasites and extracellular vesicles obtained from parasites for cancer treatment. The aim of the present invention is to use parasites and extracellular vesicles obtained from parasites in cancer treatment and to load active substances onto the exosomes by using the drug loading capacity of the exosomes and thus to carry the specific drug directly to the target cancer cells without causing any side effects on healthy cells and thereby to increase the bioavailability of the drug to achieve the desired effect in the tumor-specific target area. Within the scope of the present invention, in particular, the infantile leishmania parasite is used as a source of extracellular vesicles.

This disclosure describes compounds of Formula I and Formula II, pharmaceutically acceptable salts or derivatives thereof, and pharmaceutical compositions thereof, useful in treating infections caused by parasitic protozoa, in particular protozoa of the genera Leishmania or Trypanosoma.

The application belongs to the technical field of organic synthesis chemistry, and particularly relates to an azido tellurium ether derivative and a preparation method and application thereof. In an organic solvent, an olefin, ditelluride and azidotrimethylsilane are used as raw materials, and a stirring reaction is carried out under the presence of a photocatalyst and under the condition of visible light irradiation to obtain the azido tellurium ether derivative. The method has mild reaction conditions, simple operation, high yield and good functional group compatibility, and conforms to the principle of green chemistry. Meanwhile, the azido tellurium ether derivative provided by the application has good inhibitory activity on Leishmania, which provides a drug lead compound for the development of a new type of antiparasitic drug, and has important significance for the prevention and / or treatment of Leishmaniasis.